p2y12  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91

    Structured Review

    Alomone Labs p2y12
    P2y12, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 91/100, based on 38 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p2y12/product/Alomone Labs
    Average 91 stars, based on 38 article reviews
    Price from $9.99 to $1999.99
    p2y12 - by Bioz Stars, 2022-08
    91/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Alomone Labs p2ry12
    Interaction of <t>P2RY12-positive</t> microglia with different types of Aβ-positive plaques in pathologically-staged cases. ( A – F ). P2RY12-positive microglia (green) interacting with Aβ-positive diffuse-type plaques (red) ( A , C , E ), in LPND ( A ), HPND ( C ), and AD ( E ), but not with mature-type cored plaques ( B -LPND) ( D -HPND) ( F -AD). Scale bars represent 50 μm.
    P2ry12, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p2ry12/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    p2ry12 - by Bioz Stars, 2022-08
    86/100 stars
      Buy from Supplier

    86
    Alomone Labs p2y12 receptors
    CD4 T cells express ATP-selective P2X and ADP-selective P2Y receptors. a P2 receptor mRNA levels in purified CD4 T cells were determined with qPCR using CD4 T cells isolated from healthy human subjects or Jurkat T cells (mean ± SD, n  = 3; n.d., not detected). b Total protein expression of P2Y1 and <t>P2Y12</t> receptors in human CD4 T cells before and after TCR/CD28 stimulation. The results shown are representative of n  = 3 experiments with cells from different subjects. c – d Cell surface expression of P2Y1 and P2Y12 receptors on human CD4 T cells was assessed with flow cytometry before or 72 h after TCR/CD28 stimulation. Representative histograms ( c ) and summarized data ( d ) of unstimulated (n = 5) or stimulated (n = 4) cell preparations with cells from different donors are shown (* p ÂÂ
    P2y12 Receptors, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p2y12 receptors/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    p2y12 receptors - by Bioz Stars, 2022-08
    86/100 stars
      Buy from Supplier

    Image Search Results


    Interaction of P2RY12-positive microglia with different types of Aβ-positive plaques in pathologically-staged cases. ( A – F ). P2RY12-positive microglia (green) interacting with Aβ-positive diffuse-type plaques (red) ( A , C , E ), in LPND ( A ), HPND ( C ), and AD ( E ), but not with mature-type cored plaques ( B -LPND) ( D -HPND) ( F -AD). Scale bars represent 50 μm.

    Journal: International Journal of Molecular Sciences

    Article Title: Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer’s Disease Brains

    doi: 10.3390/ijms21020678

    Figure Lengend Snippet: Interaction of P2RY12-positive microglia with different types of Aβ-positive plaques in pathologically-staged cases. ( A – F ). P2RY12-positive microglia (green) interacting with Aβ-positive diffuse-type plaques (red) ( A , C , E ), in LPND ( A ), HPND ( C ), and AD ( E ), but not with mature-type cored plaques ( B -LPND) ( D -HPND) ( F -AD). Scale bars represent 50 μm.

    Article Snippet: In addition, comparisons of immunostaining patterns were carried using an independent antibody to P2RY12 (1:250, Alomone Labs), prepared against an 18-amino acid peptide sequence that did not overlap with the immunizing sequence of the Novus antibody.

    Techniques:

    Confocal microscopy of P2RY12 and progranulin-positive microglia in pathologically staged cases. ( A – C ). Low magnification merged images of P2RY12 (green), progranulin (PGRN) (red) and DAPI (blue) in MTG of LPND ( A ), HPND ( B ) and AD cases ( C ) to show the distribution of P2RY12 and PGRN immunoreactivity through cortical layers. Scale bar represents 50 μm. ( D – F ). Higher magnification images of PGRN (red) in MTG of LPND ( D ), HPND ( E ) and AD cases ( F ) to show the distribution of immunoreactivity. Similar amounts of PGRN immunoreactivity was present in each disease group. Scale bar represents 50 μm. ( G – I ). Merged images of P2RY12with PGRNimages shown in ( D – F ) with DAPI (blue) showing expression in same cells (yellow arrows). Scale bar represents 25 μm.

    Journal: International Journal of Molecular Sciences

    Article Title: Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer’s Disease Brains

    doi: 10.3390/ijms21020678

    Figure Lengend Snippet: Confocal microscopy of P2RY12 and progranulin-positive microglia in pathologically staged cases. ( A – C ). Low magnification merged images of P2RY12 (green), progranulin (PGRN) (red) and DAPI (blue) in MTG of LPND ( A ), HPND ( B ) and AD cases ( C ) to show the distribution of P2RY12 and PGRN immunoreactivity through cortical layers. Scale bar represents 50 μm. ( D – F ). Higher magnification images of PGRN (red) in MTG of LPND ( D ), HPND ( E ) and AD cases ( F ) to show the distribution of immunoreactivity. Similar amounts of PGRN immunoreactivity was present in each disease group. Scale bar represents 50 μm. ( G – I ). Merged images of P2RY12with PGRNimages shown in ( D – F ) with DAPI (blue) showing expression in same cells (yellow arrows). Scale bar represents 25 μm.

    Article Snippet: In addition, comparisons of immunostaining patterns were carried using an independent antibody to P2RY12 (1:250, Alomone Labs), prepared against an 18-amino acid peptide sequence that did not overlap with the immunizing sequence of the Novus antibody.

    Techniques: Confocal Microscopy, Expressing

    Quantitative biochemical measurements of P2RY12 protein and mRNA in human brains. ( A–C ). Western blot measurements of P2RY12 levels in MTG samples from LP, HP and AD brains. ( A ). Representative western blot image of P2RY12 polypeptide of MTG protein extracts identified with Novus antibody. Blots were normalized for levels of β actin. ( B ). Scatter plot showing individual P2RY12 expression levels. Significant decrease in protein levels of 58 kDa full-length P2RY12 band in AD (green shapes) compared to LPND (black) and HPND (red) cases. Chart indicates mean + Standard error of mean (SEM). Statistical analysis by one-way ANOVA with Tukey post-hoc test (F 2,26 = 11.54, p

    Journal: International Journal of Molecular Sciences

    Article Title: Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer’s Disease Brains

    doi: 10.3390/ijms21020678

    Figure Lengend Snippet: Quantitative biochemical measurements of P2RY12 protein and mRNA in human brains. ( A–C ). Western blot measurements of P2RY12 levels in MTG samples from LP, HP and AD brains. ( A ). Representative western blot image of P2RY12 polypeptide of MTG protein extracts identified with Novus antibody. Blots were normalized for levels of β actin. ( B ). Scatter plot showing individual P2RY12 expression levels. Significant decrease in protein levels of 58 kDa full-length P2RY12 band in AD (green shapes) compared to LPND (black) and HPND (red) cases. Chart indicates mean + Standard error of mean (SEM). Statistical analysis by one-way ANOVA with Tukey post-hoc test (F 2,26 = 11.54, p

    Article Snippet: In addition, comparisons of immunostaining patterns were carried using an independent antibody to P2RY12 (1:250, Alomone Labs), prepared against an 18-amino acid peptide sequence that did not overlap with the immunizing sequence of the Novus antibody.

    Techniques: Western Blot, Expressing

    Proposed scheme of arrangement of different P2RY12-expressing microglia around Aβ plaques. Suggested scheme to describe localized areas of microglial inflammation around plaques. Zone 1: microglia interacting with mature plaques (HLA-DR high, P2RY12 negative) producing proinflammatory cytokines. Zone 2: Area adjacent to plaque with low or negative P2RY12 positive microglia. Zone 3. P2RY12 high expression in surrounding area defining the boundary between proinflammatory area (Zone 1 and 2) and non-affected area (Zone 3 and beyond). As described in this report, exceptions to this scheme were observed.

    Journal: International Journal of Molecular Sciences

    Article Title: Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer’s Disease Brains

    doi: 10.3390/ijms21020678

    Figure Lengend Snippet: Proposed scheme of arrangement of different P2RY12-expressing microglia around Aβ plaques. Suggested scheme to describe localized areas of microglial inflammation around plaques. Zone 1: microglia interacting with mature plaques (HLA-DR high, P2RY12 negative) producing proinflammatory cytokines. Zone 2: Area adjacent to plaque with low or negative P2RY12 positive microglia. Zone 3. P2RY12 high expression in surrounding area defining the boundary between proinflammatory area (Zone 1 and 2) and non-affected area (Zone 3 and beyond). As described in this report, exceptions to this scheme were observed.

    Article Snippet: In addition, comparisons of immunostaining patterns were carried using an independent antibody to P2RY12 (1:250, Alomone Labs), prepared against an 18-amino acid peptide sequence that did not overlap with the immunizing sequence of the Novus antibody.

    Techniques: Expressing

    Quantitative measurements of P2RY12 immunoreactive structures in human brain tissue sections. ( A , B ). Measurements of area occupied of P2RY12 immunoreactivity in LPND ( n = 11) (black), HPND ( n = 11) (red) and AD ( n = 12) (green) cases. ( A ). Sections were imaged at 4x magnification (three random areas/cases) and area occupied in thresholded images measured using Image J software. Results show significant decrease between HPND and AD cases. Statistical analysis by one-way ANOVA with Tukey post-hoc test (F 2,29 = 3.903, p

    Journal: International Journal of Molecular Sciences

    Article Title: Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer’s Disease Brains

    doi: 10.3390/ijms21020678

    Figure Lengend Snippet: Quantitative measurements of P2RY12 immunoreactive structures in human brain tissue sections. ( A , B ). Measurements of area occupied of P2RY12 immunoreactivity in LPND ( n = 11) (black), HPND ( n = 11) (red) and AD ( n = 12) (green) cases. ( A ). Sections were imaged at 4x magnification (three random areas/cases) and area occupied in thresholded images measured using Image J software. Results show significant decrease between HPND and AD cases. Statistical analysis by one-way ANOVA with Tukey post-hoc test (F 2,29 = 3.903, p

    Article Snippet: In addition, comparisons of immunostaining patterns were carried using an independent antibody to P2RY12 (1:250, Alomone Labs), prepared against an 18-amino acid peptide sequence that did not overlap with the immunizing sequence of the Novus antibody.

    Techniques: Software

    Distribution of P2RY12 microglia within cortical layers in relation to amyloid beta plaques in pathologically staged samples ( A – C ). Lower magnification photomicrographs showing the changes in P2RY12 microglia distribution compared to Aβ plaques within cortical layers of MTG. Sections from low plaque, high plaque and AD cases stained for P2RY12 (purple) and Aβ (brown). Sections were counterstained with neutral red to identity cellular morphology. Scale bars represent 200 μm. ( D – F ). Higher magnification photomicrographs of the areas in panels ( A – C ) indicated by frames. Scale bars represent 50 μm.

    Journal: International Journal of Molecular Sciences

    Article Title: Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer’s Disease Brains

    doi: 10.3390/ijms21020678

    Figure Lengend Snippet: Distribution of P2RY12 microglia within cortical layers in relation to amyloid beta plaques in pathologically staged samples ( A – C ). Lower magnification photomicrographs showing the changes in P2RY12 microglia distribution compared to Aβ plaques within cortical layers of MTG. Sections from low plaque, high plaque and AD cases stained for P2RY12 (purple) and Aβ (brown). Sections were counterstained with neutral red to identity cellular morphology. Scale bars represent 200 μm. ( D – F ). Higher magnification photomicrographs of the areas in panels ( A – C ) indicated by frames. Scale bars represent 50 μm.

    Article Snippet: In addition, comparisons of immunostaining patterns were carried using an independent antibody to P2RY12 (1:250, Alomone Labs), prepared against an 18-amino acid peptide sequence that did not overlap with the immunizing sequence of the Novus antibody.

    Techniques: Staining

    Features of P2RY12-immunoreactive microglia. ( A , B ). Morphology of P2RY12-immunoreactive microglia (purple) in a low plaque non-demented (LPND) case ( A ) and AD case ( B ). Sections of middle temporal gyrus (MTG) were single-stained with antibody to P2RY12. Red arrows in panel B illustrate the lack of P2RY12 immunoreactive cells in an area occupied by plaque. ( C , D ). P2RY12-immunoreactive microglia (purple) are a feature in hippocampus sections from non-demented (ND) case ( H ) and Alzheimer’s disease (AD) case. Section shows staining in CA2 region of hippocampus. Continued presence of P2RY12-positive microglia in AD hippocampus ( D ) was noticeable. ( E , F ). Double-staining of section of ND and AD case with P2RY12 (purple) and HLA-DR (brown) showed limited overlap. HLA-DR-positive microglial clusters over plaques were P2RY12-negative except for single cells observed within the cluster (arrows). ( G , H ). Interaction of P2RY12-immunoreactive microglia (purple) and Aβ plaques (brown). The panels show two types of interactions of P2RY12-positive microglia with plaques. Positive microglia are not present in close association with mature cored plaque ( G ), while they are present in close association with diffuse type of plaques ( H ). Specificity controls for P2RY12 staining of microglia. ( I , J ). Staining of representative sections with P2RY12 (Novus) antibody preabsorbed with immunizing peptide (I, +Pep) compared to staining of matched section with P2RY12 antibody non-absorbed ( J , -Pep). ( K , L ). Staining of matched sections with alternative P2RY12 antibody. Same staining pattern of microglia revealed with P2RY12 (Novus) antibody ( C ) as with P2RY12 (Alomone Labs) antibody (D ). Sections reacted with Alomone Lab P2RY12 required antigen retrieval to obtain positive staining pattern. All sections shown had been counterstained with neutral red to identify nuclei (red color). Abbreviations: ND: non-demented. AD: Alzheimer’s disease. MTG: middle temporal gyrus.—Pep: antibody without immunizing peptide. + Pep: antibody with immunizing peptide. Scale bars represent 50 μm.

    Journal: International Journal of Molecular Sciences

    Article Title: Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer’s Disease Brains

    doi: 10.3390/ijms21020678

    Figure Lengend Snippet: Features of P2RY12-immunoreactive microglia. ( A , B ). Morphology of P2RY12-immunoreactive microglia (purple) in a low plaque non-demented (LPND) case ( A ) and AD case ( B ). Sections of middle temporal gyrus (MTG) were single-stained with antibody to P2RY12. Red arrows in panel B illustrate the lack of P2RY12 immunoreactive cells in an area occupied by plaque. ( C , D ). P2RY12-immunoreactive microglia (purple) are a feature in hippocampus sections from non-demented (ND) case ( H ) and Alzheimer’s disease (AD) case. Section shows staining in CA2 region of hippocampus. Continued presence of P2RY12-positive microglia in AD hippocampus ( D ) was noticeable. ( E , F ). Double-staining of section of ND and AD case with P2RY12 (purple) and HLA-DR (brown) showed limited overlap. HLA-DR-positive microglial clusters over plaques were P2RY12-negative except for single cells observed within the cluster (arrows). ( G , H ). Interaction of P2RY12-immunoreactive microglia (purple) and Aβ plaques (brown). The panels show two types of interactions of P2RY12-positive microglia with plaques. Positive microglia are not present in close association with mature cored plaque ( G ), while they are present in close association with diffuse type of plaques ( H ). Specificity controls for P2RY12 staining of microglia. ( I , J ). Staining of representative sections with P2RY12 (Novus) antibody preabsorbed with immunizing peptide (I, +Pep) compared to staining of matched section with P2RY12 antibody non-absorbed ( J , -Pep). ( K , L ). Staining of matched sections with alternative P2RY12 antibody. Same staining pattern of microglia revealed with P2RY12 (Novus) antibody ( C ) as with P2RY12 (Alomone Labs) antibody (D ). Sections reacted with Alomone Lab P2RY12 required antigen retrieval to obtain positive staining pattern. All sections shown had been counterstained with neutral red to identify nuclei (red color). Abbreviations: ND: non-demented. AD: Alzheimer’s disease. MTG: middle temporal gyrus.—Pep: antibody without immunizing peptide. + Pep: antibody with immunizing peptide. Scale bars represent 50 μm.

    Article Snippet: In addition, comparisons of immunostaining patterns were carried using an independent antibody to P2RY12 (1:250, Alomone Labs), prepared against an 18-amino acid peptide sequence that did not overlap with the immunizing sequence of the Novus antibody.

    Techniques: Staining, Double Staining

    Expression of P2RY12 mRNA and protein by in vitro cultures of human microglia. ( A ). Interleukin-4 stimulates P2RY12 mRNA expression. Bar chart showing results real time PCR analysis for P2RY12 mRNA of human microglia stimulated with indicated agents. Results of analysis of single human microglia case (each in triplicate) and representative of other analyses. Abbreviations: Con, control unstimulated: IL-4, interleukin-4 (40 ng/mL): Aβ2 and Aββ5 (Aβ (1–42) 2 μM and 5 μM): IFNγ, interferon-γ (100 ng/mL): LPS, lipopolysaccharide (100 ng/mL): LPS/IFNγ (doses combined): IL-6, interleukin-6 (40 ng/mL). **** p

    Journal: International Journal of Molecular Sciences

    Article Title: Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer’s Disease Brains

    doi: 10.3390/ijms21020678

    Figure Lengend Snippet: Expression of P2RY12 mRNA and protein by in vitro cultures of human microglia. ( A ). Interleukin-4 stimulates P2RY12 mRNA expression. Bar chart showing results real time PCR analysis for P2RY12 mRNA of human microglia stimulated with indicated agents. Results of analysis of single human microglia case (each in triplicate) and representative of other analyses. Abbreviations: Con, control unstimulated: IL-4, interleukin-4 (40 ng/mL): Aβ2 and Aββ5 (Aβ (1–42) 2 μM and 5 μM): IFNγ, interferon-γ (100 ng/mL): LPS, lipopolysaccharide (100 ng/mL): LPS/IFNγ (doses combined): IL-6, interleukin-6 (40 ng/mL). **** p

    Article Snippet: In addition, comparisons of immunostaining patterns were carried using an independent antibody to P2RY12 (1:250, Alomone Labs), prepared against an 18-amino acid peptide sequence that did not overlap with the immunizing sequence of the Novus antibody.

    Techniques: Expressing, In Vitro, Real-time Polymerase Chain Reaction

    Confocal microscopy of P2RY12 and HLA-DR positive microglia in pathologically staged cases. ( A – I ) Images of P2RY12 (green), HLA-DR (red) and merged (yellow) with DAPI (blue) in MTG of LPND ( A – C ), HPND ( D – F ) and AD case ( G – I ) to show the distribution of P2RY12 and HLA-DR immunoreactivity. Examples of colocalization (yellow arrows) are shown in Merge image. Scale bar represents 50 μm.

    Journal: International Journal of Molecular Sciences

    Article Title: Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer’s Disease Brains

    doi: 10.3390/ijms21020678

    Figure Lengend Snippet: Confocal microscopy of P2RY12 and HLA-DR positive microglia in pathologically staged cases. ( A – I ) Images of P2RY12 (green), HLA-DR (red) and merged (yellow) with DAPI (blue) in MTG of LPND ( A – C ), HPND ( D – F ) and AD case ( G – I ) to show the distribution of P2RY12 and HLA-DR immunoreactivity. Examples of colocalization (yellow arrows) are shown in Merge image. Scale bar represents 50 μm.

    Article Snippet: In addition, comparisons of immunostaining patterns were carried using an independent antibody to P2RY12 (1:250, Alomone Labs), prepared against an 18-amino acid peptide sequence that did not overlap with the immunizing sequence of the Novus antibody.

    Techniques: Confocal Microscopy

    Features of P2RY12-positive microglia interacting with phosphorylated tau-containing structures. ( A–F ). Dual-color DAB enzyme histochemistry illustrating different features of P2RY12-positive microglia (purple) with phosphorylated tau-positive structures (brown). Abbreviations: LPND; low plaque non-demented. HPND; high plaque non-demented. AD; Alzheimer’s disease. MTG; middle temporal gyrus. Scale bars represent 50 μm. ( G – I ). Dual-color laser confocal histochemistry showing interaction of P2RY12 positive microglia with early intracellular tangle in LPND case ( G ). Features of P2RY12-positive microglia interacting with mature tangle ( H ) and neuritic plaque ( I ) in AD cases. Scale bars represent 50 μm.

    Journal: International Journal of Molecular Sciences

    Article Title: Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer’s Disease Brains

    doi: 10.3390/ijms21020678

    Figure Lengend Snippet: Features of P2RY12-positive microglia interacting with phosphorylated tau-containing structures. ( A–F ). Dual-color DAB enzyme histochemistry illustrating different features of P2RY12-positive microglia (purple) with phosphorylated tau-positive structures (brown). Abbreviations: LPND; low plaque non-demented. HPND; high plaque non-demented. AD; Alzheimer’s disease. MTG; middle temporal gyrus. Scale bars represent 50 μm. ( G – I ). Dual-color laser confocal histochemistry showing interaction of P2RY12 positive microglia with early intracellular tangle in LPND case ( G ). Features of P2RY12-positive microglia interacting with mature tangle ( H ) and neuritic plaque ( I ) in AD cases. Scale bars represent 50 μm.

    Article Snippet: In addition, comparisons of immunostaining patterns were carried using an independent antibody to P2RY12 (1:250, Alomone Labs), prepared against an 18-amino acid peptide sequence that did not overlap with the immunizing sequence of the Novus antibody.

    Techniques:

    Different microglial morphologies associated with P2RY12 expression. Representative immunohistochemistry results of tissue sections stained to identify P2RY12 (purple) alone and Aβ (brown), IBA-1 or phosphorylated tau. ( A ). Ramified microglia in LPND case. ( B , C ). Microglia with fragmented morphology in HPND cases. ( C ). Fragmented microglia associated with diffuse Aβ plaques. ( D ). P2RY12 microglia with tufted morphology in AD case. ( E , F ). Colocalization of P2RY12 and IBA-1. ( E ). Rod shaped IBA-1-positive microglia (brown arrow) with minimal P2RY12 immunoreactivity. P2RY12-positive, IBA-1-positive microglia (arrowheads ( E , F )). All P2RY12 immunoreactive microglia showed some IBA-1 immunoreactivity. ( F ). IBA-1 positive cluster surrounded by P2RY12 microglia. ( G – I ). Different morphologies of P2RY12-positive microglia interacting with Aβ plaques. ( G ). P2RY12-positive microglia with long processes interacting with diffuse plaques in HPND case. ( H , I ). P2RY12-positve microglia with activated morphologies (large cell bodies, short processes) interacting with dense Aβ plaques. ( J , K ). P2RY12-positive rod-shaped microglia in LPND ( J ) and HPND ( K ) sections. ( L ) P2RY12-positive microglial processes show interactions with neurons. Scale bars represent 50 μm.

    Journal: International Journal of Molecular Sciences

    Article Title: Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer’s Disease Brains

    doi: 10.3390/ijms21020678

    Figure Lengend Snippet: Different microglial morphologies associated with P2RY12 expression. Representative immunohistochemistry results of tissue sections stained to identify P2RY12 (purple) alone and Aβ (brown), IBA-1 or phosphorylated tau. ( A ). Ramified microglia in LPND case. ( B , C ). Microglia with fragmented morphology in HPND cases. ( C ). Fragmented microglia associated with diffuse Aβ plaques. ( D ). P2RY12 microglia with tufted morphology in AD case. ( E , F ). Colocalization of P2RY12 and IBA-1. ( E ). Rod shaped IBA-1-positive microglia (brown arrow) with minimal P2RY12 immunoreactivity. P2RY12-positive, IBA-1-positive microglia (arrowheads ( E , F )). All P2RY12 immunoreactive microglia showed some IBA-1 immunoreactivity. ( F ). IBA-1 positive cluster surrounded by P2RY12 microglia. ( G – I ). Different morphologies of P2RY12-positive microglia interacting with Aβ plaques. ( G ). P2RY12-positive microglia with long processes interacting with diffuse plaques in HPND case. ( H , I ). P2RY12-positve microglia with activated morphologies (large cell bodies, short processes) interacting with dense Aβ plaques. ( J , K ). P2RY12-positive rod-shaped microglia in LPND ( J ) and HPND ( K ) sections. ( L ) P2RY12-positive microglial processes show interactions with neurons. Scale bars represent 50 μm.

    Article Snippet: In addition, comparisons of immunostaining patterns were carried using an independent antibody to P2RY12 (1:250, Alomone Labs), prepared against an 18-amino acid peptide sequence that did not overlap with the immunizing sequence of the Novus antibody.

    Techniques: Expressing, Immunohistochemistry, Staining

    Confocal microscopy of P2RY12 and CD68-positive microglia in pathologically staged cases. A – C). Low magnification merged images of P2RY12 (green), CD68 (red) and DAPI (blue) in MTG of LPND ( A ), HPND ( B ) and AD cases ( C ) to show the distribution of P2RY12 and CD68 immunoreactivity through cortical layer. Scale bars represent 50 μm. ( D – F ). Higher magnification merged images of CD68 (red) in MTG of LPND ( D ), HPND ( E ) and AD cases ( F ) to show the distribution of CD68 immunoreactivity. Similar amounts of CD68 immunoreactivity was present in each disease group. Scale bars represent 50 μm. ( G – I ). Merged images of P2RY12 (green) with the CD68 (red) images shown in ( D , E )) with DAPI (blue). Scale bars represent 50 μm.

    Journal: International Journal of Molecular Sciences

    Article Title: Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer’s Disease Brains

    doi: 10.3390/ijms21020678

    Figure Lengend Snippet: Confocal microscopy of P2RY12 and CD68-positive microglia in pathologically staged cases. A – C). Low magnification merged images of P2RY12 (green), CD68 (red) and DAPI (blue) in MTG of LPND ( A ), HPND ( B ) and AD cases ( C ) to show the distribution of P2RY12 and CD68 immunoreactivity through cortical layer. Scale bars represent 50 μm. ( D – F ). Higher magnification merged images of CD68 (red) in MTG of LPND ( D ), HPND ( E ) and AD cases ( F ) to show the distribution of CD68 immunoreactivity. Similar amounts of CD68 immunoreactivity was present in each disease group. Scale bars represent 50 μm. ( G – I ). Merged images of P2RY12 (green) with the CD68 (red) images shown in ( D , E )) with DAPI (blue). Scale bars represent 50 μm.

    Article Snippet: In addition, comparisons of immunostaining patterns were carried using an independent antibody to P2RY12 (1:250, Alomone Labs), prepared against an 18-amino acid peptide sequence that did not overlap with the immunizing sequence of the Novus antibody.

    Techniques: Confocal Microscopy

    CD4 T cells express ATP-selective P2X and ADP-selective P2Y receptors. a P2 receptor mRNA levels in purified CD4 T cells were determined with qPCR using CD4 T cells isolated from healthy human subjects or Jurkat T cells (mean ± SD, n  = 3; n.d., not detected). b Total protein expression of P2Y1 and P2Y12 receptors in human CD4 T cells before and after TCR/CD28 stimulation. The results shown are representative of n  = 3 experiments with cells from different subjects. c – d Cell surface expression of P2Y1 and P2Y12 receptors on human CD4 T cells was assessed with flow cytometry before or 72 h after TCR/CD28 stimulation. Representative histograms ( c ) and summarized data ( d ) of unstimulated (n = 5) or stimulated (n = 4) cell preparations with cells from different donors are shown (* p ÂÂ

    Journal: Purinergic Signalling

    Article Title: Autocrine stimulation of P2Y1 receptors is part of the purinergic signaling mechanism that regulates T cell activation

    doi: 10.1007/s11302-019-09653-6

    Figure Lengend Snippet: CD4 T cells express ATP-selective P2X and ADP-selective P2Y receptors. a P2 receptor mRNA levels in purified CD4 T cells were determined with qPCR using CD4 T cells isolated from healthy human subjects or Jurkat T cells (mean ± SD, n  = 3; n.d., not detected). b Total protein expression of P2Y1 and P2Y12 receptors in human CD4 T cells before and after TCR/CD28 stimulation. The results shown are representative of n  = 3 experiments with cells from different subjects. c – d Cell surface expression of P2Y1 and P2Y12 receptors on human CD4 T cells was assessed with flow cytometry before or 72 h after TCR/CD28 stimulation. Representative histograms ( c ) and summarized data ( d ) of unstimulated (n = 5) or stimulated (n = 4) cell preparations with cells from different donors are shown (* p ÂÂ

    Article Snippet: Because P2Y13 receptor expression was barely detectable in primary CD4 T cells and Jurkat cells, we focused on P2Y1 and P2Y12 receptors.

    Techniques: Purification, Real-time Polymerase Chain Reaction, Isolation, Expressing, Flow Cytometry, Cytometry